Human MMP14 (KD014) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Matrix metalloproteinase-14 (MMP14) is a ~65 kDa protein. Endopeptidase that degrades various components of the extracellular matrix such as collagen. Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development. Activates progelatinase A/MMP2, thereby acting as a positive regulator of cell growth and migration. Involved in the formation of the fibrovascular tissues in association with pro-MMP2. May be involved in actin cytoskeleton reorganization by cleaving PTK7.
KD014 (0.1-50 ug/mL; 3 days) has no effect on the viability of 4T1 or E0771 mouse breast cancer cells [1]. KD014 (0.2-100 ug/mL) significantly inhibits the invasive ability of 4T1 mouse breast cancer cells through type I collagen matrix in a dose-dependent manner [1]. KD014 (100-500 nM; 4 days) dose-dependently inhibits the degradation of collagen membranes by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) [2]. KD014 (100-500 nM; 4 weeks) dose-dependently inhibits the invasion of bovine nasal cartilage by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) [2]. Cell Invasion Assay [1] Cell Line: 4T1 murine breast carcinoma cells Concentration: 0.2, 2.0, 20, 100 ug/mL Incubation Time: / Result: Inhibited 4T1 cell invasion through a collagen matrix in a dose-dependent manner. Exhibited statistically significant inhibition at all tested concentrations (P =.0314 at 0.2 ug/mL to P =.0004 at 100 ug/mL). Cell Invasion Assay [2] Cell Line: human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) Concentration: 100 nM; 500 nM Incubation Time: 4 weeks Result: Inhibited the invasion of human RA FLS into bovine nasal cartilage explants in a dose-dependent manner, as shown by reduced presence of invading cells compared to control. KD014 (10 mg/kg; i.p.; once every 48 hours; up to 10 injections) inhibits tumor growth in 4T1 and E0771 orthotopic breast cancer mouse models [1]. KD014 (20-40 mg/kg; i.p.; once every other day for 10 days) significantly inhibits articular cartilage degradation and blocks arthritis progression in a mouse collagen-induced arthritis model [2].
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
